Area of research
Obstetrics and Gynecology · Molecular Biology
Research interest
Research topics from publications: Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts. Representative work: 5524 Background: The effectiveness of immune checkpoint inhibitors for treating patients with advanced cervical cancer or platinum-resistant recurrent ovarian cancer (PROC) has been demonstrated in clinical studies. However, the current treatment options have not fully met the clinical needs of these patients. Since 2021, a Phase Ib/IIa trial was conducted in China to assess the safety and efficacy of PM8002, a bispecific antibody that targets both PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors. Preliminary clinical data was presented at SITC2022 (abstract #725) and ASCO2023 (abstract #2536). Here, we present an update of our study for cervical cancer and PROC cohorts. Meth